Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Collaboration › Details

Boundless Bio–Leucadia: investor conference, 202306 supply service Boundless Bio presents at Jefferies 2023 Global Healthcare Conference


Period Period 2023-06-08
Organisations Partner, 1st Boundless Bio Inc.
  Partner, 2nd Jefferies LLC
  Group Leucadia (Group)
Products Product Jefferies 2023 Global Healthcare Conference New York
  Product 2 cancer drug

Boundless Bio, Inc.. (6/1/23). "Press Release: Boundless Bio to Present at the 2023 Jefferies Healthcare Conference". San Diego, CA.

Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, today announced that Chief Medical Officer, Klaus Wagner, M.D., Ph.D., will present at the 2023 Jefferies Healthcare Conference which will take place in New York City. Presentation details are as follows:

Date: Thursday, June 8, 2023
Time: 4:00 – 4:25 PM ET
Location: New York Marriott Marquis

About Boundless Bio

Boundless Bio is a clinical stage, next-generation precision oncology company dedicated to the discovery and development of new drugs targeting a novel area of cancer biology, ecDNA, to deliver transformative therapies intended to improve and extend the lives of patients with oncogene amplified cancers.

For more information, visit

Follow us on LinkedIn and Twitter.


James Lee, Boundless Bio

Dan Budwick, 1AB

Record changed: 2023-06-06


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Boundless Bio Inc.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px

» top